Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COMy 2019 | Progression of multiple myeloma novel therapies with Prof. Nagler

Arnon Nagler • 17 May 2019
COMy 2019
Multiple Myeloma

Speaking at the Controversies in Multiple Myeloma (Comy) 2019 World Congress in Paris, France, Arnon Nagler, MD, of the Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses the difference and progression of treatment options for multiple myeloma from 10 years ago compared to now. Prof. Nagler emphasizes the improvement in complete and overall response, but also the high cost of certain novel agents.

More from Arnon Nagler

Evaluating the impact of donor age on alloSCT outcomes in patients with secondary AML in CR1 2:01
Evaluating the impact of donor age on alloSCT outcomes in patients with secondary AML in CR1
Arnon Nagler • 6 Dec 2025
Transplanting patients with advanced AML 3:07
Transplanting patients with advanced AML
Arnon Nagler • 30 Mar 2025
Bone marrow versus mobilized peripheral blood grafts for haploidentical transplant in secondary AML 1:42
Bone marrow versus mobilized peripheral blood grafts for haploidentical transplant in secondary AML
Arnon Nagler • 30 Mar 2025
Is there a preferable donor for alloSCT in secondary AML in first complete remission? 2:23
Is there a preferable donor for alloSCT in secondary AML in first complete remission?
Arnon Nagler • 30 Mar 2025

Related Videos

Initial results from MajesTEC-3: Tec-Dara versus DPd/DVd in patients with R/R multiple myeloma 3:53
Initial results from MajesTEC-3: Tec-Dara versus DPd/DVd in patients with R/R multiple myeloma
Luciano Costa • 16 Dec 2025
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8 4:02
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac • 10 Dec 2025
Incidence and risk factors for infections in NDMM treated with modern induction regimens 1:54
Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis • 7 Dec 2025
A real-world analysis of infections in patients with RRMM receiving ide-cel 3:59
A real-world analysis of infections in patients with RRMM receiving ide-cel
Muhammad Bilal Abid • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals